key: cord-0957636-hh4g49z1
authors: McAdam, Alexander J.
title: Cycle threshold values from SARS-CoV-2 PCR assays: Interpretation and potential use cases
date: 2022-02-21
journal: Clin Lab Med
DOI: 10.1016/j.cll.2022.02.003
sha: 63f75ce28b365d0a3bad4d19bc5cee76e4028287
doc_id: 957636
cord_uid: hh4g49z1

Reverse-transcription polymerase chain reaction (RT-PCR) tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), are approved for qualitative use. The cycle threshold (Ct) value reflects the concentration of viral RNA in the sample, with lower Ct values indicating higher levels of RNA. Caregivers may wish to use the Ct value to determine progression of infection, how severe the infection will be and whether the patient can transmit the virus. Variability of Ct values and the data supporting these uses should be considered when deciding whether and how to use Ct values in clinical care.

The coronavirus disease 2019 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused over 381 million infections and over 5.6 million deaths, worldwide, including over 75 million infections and over 890,000 deaths in the United States. 1 While use of vaccines has slowed the mortality rates in many places, lack of access to vaccines and vaccine hesitancy have resulted in continued infections and deaths. Diagnostic testing for SARS-CoV-2 has been and will continue to be critical to addressing the pandemic.

The mainstay of diagnostic testing is nucleic acid amplified tests, primarily using reverse transcription followed by polymerase chain reaction (RT-PCR). RT-PCR tests for SARS-CoV-2 are designed and validated to be used as qualitative tests, reporting as positive if the virus is detected or negative if it is not. RT-PCR can be made quantitative if a standard curve is generated using known concentrations of virus or viral RNA, allowing use of the sample cycle threshold (Ct) at which viral RNA is detected to estimate the quantity of virus present. Alternatively, the Ct value alone can be used directly, as a semiquantitative way to compare the level of virus between two samples run using the same assay on the same platform.

There are several sources of variability in Ct values, and these are discussed separately in the sections that follow. In considering these sources of variability, several things should be kept in mind. First, the methods used in these studies vary significantly. For brevity, the most important differences in methods will be discussed, but less important differences will not. Second, these papers often show summary data, such as means and standard deviations, graphically, but they may not provide the numerical values. In such cases, differences between Ct values have been estimated by inspection of the figures.

Third, these papers often include separate analysis of the targets of amplification for those assays that include more than one target. For the most part, the different targets within a specific assay do not vary much in their Ct values, and so this level of detail will not be discussed except where necessary.

Different RT-PCR tests for SARS-CoV-2 can yield very different Ct values. This is to be expected, given that the assays amplify different regions of the viral genome using different primers and probes and include different reagents, all of which will contribute to variations in the efficiency of the RT-PCR between assays. Reasonably comprehensive data on this issue were provided by the College of American Pathologists (CAP) Microbiology Committee in response to a paper in Clinical Infectious Diseases. 6 These data were collected from participants using CAP proficiency test materials. The median Ct values between different tests varied by as much as 14 cycles. Even within a single gene target on a single assay, between-laboratory results varied by up to 12 cycles. Papers in which various assays were validate or compared have similarly found differences in Ct values that ranged from 5 to slightly more than 14 cycles. 7, 8 Importantly, because of high test volumes and the need for reasonable turn-aroundtime, many laboratories have had to run several different assays. Potentially large differences in the Ct J o u r n a l P r e -p r o o f values between assays must be considered if values are compared between assays performed in different or the same laboratory.

The effect of dilution and storage of SARS-CoV-2 in different media, including M4, minimal essential media (MEM), phosphate buffered saline, 0.9% saline, as well as in patient samples (sputum and bronchoalveolar lavage) has been evaluated. Briefly, two studies, each which included several prospective transport media or sample types, demonstrated that there was no increase greater than two in the Ct values for any media or sample type following storage at temperatures ranging from room temperature to -10 to -30°C during seven days of storage. 9,10 Ct increases of slightly more than 2 were seen after storage of samples in saline after 14 days at refrigerator or freezer temperatures. In a third study, storage of SARS-CoV-2 in phosphate buffered saline at room temperature, 4°C, -20°C and -80°C had little effect on the Ct at 7 days. 11 From 14 to 28 days, samples with a lower level of virus (500-1,000 copies/mL) had increased Ct values of slightly more than two, and some samples became negative at room temperature, 4°C, and -20°C but not at -80°C. Samples with a higher level of virus (5,000 to 10,000 copies/mL) did not show significant changes in the Ct values at any of these temperatures. In summary, storage at room temperature or 4C for up to a week has minimal effect on the Ct values for SARS-CoV-2, but if samples are stored longer there may be small increases of 2-3 Ct and lower levels of virus may become undetectable.

There are sizable differences in the Ct values of different types of respiratory samples. Several studies compare the Ct values between different specimens of the upper respiratory tract. Saliva will be included here, because it presumably represents a mixture of saliva and mucosal upper respiratory tract J o u r n a l P r e -p r o o f secretions, with the latter presumably containing SARS-CoV-2 RNA. Because there is so much variation in the methods of sample collection and processing, the findings are generally specific to the institution where the study was conducted, so only a few general points can be made. First, nasopharyngeal samples usually have Ct values lower than or equal to other sample types studied. Compared to nasopharyngeal samples, nasal swabs 12 , saliva 13, 14 , and oral swabs 14 have values that are approximately 5 to7 cycles higher in some studies. Other studies have found similar Ct values for nasopharyngeal and nasal swabs 13 , or for nasopharyngeal swabs, throat swabs, sputum and dual throat/nasopharyngeal samples. 15 A small study found that Ct values of tracheal aspirates were on average 3 cycles higher than those of nasopharyngeal swabs. 16 When the Ct values were normalized to the human RNaseP gene that was included in the assay, there was no difference between the values from tracheal aspirate and nasopharyngeal swab specimens 16 , however the meaning of standardizing Ct values of viral RNA to human RNA is not clear.

At the time of writing, there were no studies that compared Ct values for SARS-CoV-2 PCR between samples from the upper respiratory tract and the lower respiratory tract. There are case reports and case series that show that qualitative results of bronchoalveolar lavage samples differ from those of NP swabs or other upper respiratory samples. 17 These reports usually emphasize the importance of testing lower respiratory samples to optimize detection of SARS-CoV-2. Given these discrepant results, and the sample dilution required to collect a bronchoalveolar lavage sample, it is inevitable that there will be differences between Ct values of upper and lower respiratory samples. It is unlikely that the sample matrix will greatly affect the Ct values, at least if the method of RNA purification is adequate and consistent. 11 It is strongly recommended that the same sample type and assay be used to compare Ct values within a patient over time, unless there is sufficient local data to allow providers to make informed comparisons.

There are three potential uses of Ct values that are adequately discussed in the literature to merit review. These include, first, possible use of Ct values to evaluate the progression or course of COVID-19, second, the prognostic use of Ct values as predictors of clinical severity of infection and, third, use of Ct values to determine whether a patient is potentially infectious.

Caregivers may want to use the Ct value or multiple Ct values to determine whether the viral load is rising or falling, as a marker of whether the patient is recovering from infection. A similar, but perhaps less common use, is to use the Ct to try to determine approximately how long the patient has been infected. The utility of the Ct value for these applications depends on several things, including the average kinetics of the viral load (and associated Ct) in affected persons, the variability of these kinetics within an individual patient, and how the kinetics differ in patients who are immunocompromised. Each of these will be discussed.

A study early in the pandemic provided pooled and individual-patient data on the Ct values of patients with acute COVID-19. 18 While the number of patients is small at 14, the study is valuable because the trends over time after the onset of symptoms are shown for individual patients. Nasal (mid-turbinate and nasopharyngeal) swabs or throat swabs were analyzed separately, using RT-PCR which detected regions of the N and ORF1b genes. Ct values for ORF1b were tracked over time for each patient. From this study, it is clear that aggregated Ct values are lower in the first week after symptom onset, and then higher thereafter for both specimen types, with nearly all patients having negative results by 21 days after symptom onset. However, there is marked variability in Ct values between and within patients.

From inspection of the graphs, for each of the two specimen types, at least five patients had samples J o u r n a l P r e -p r o o f that were negative followed by samples that were positive for SARS-CoV-2. Furthermore, although the aggregate Ct values rose over time, indicating falling levels of viral RNA, several patients had decreases in the Ct values of greater than eight to ten, followed by rising Ct values or negative results. Taken together, these results indicate that results within an individual patient can be highly variable, and so using a small number of Ct values to track a patients course may be misleading.

Numerous case reports and case series show that people who are immunocompromised can have prolonged infection with SARS-CoV-2. The largest of these includes 20 patients receiving immunosuppressive therapies for various cancers. 19 Unfortunately, the publication does not include Ct values, however RT-PCR results are summarized and detection of replication-competent virus is presented in some detail. Viral RNA could be detected as late as 78 days after onset of symptoms (interquartile range, 24 to 64 days). Three of 20 patients shed replication competent virus for more than 20 days. A smaller series, including only 3 patients with varies causes of immunosuppression and prolonged infection with SARS-CoV-2, includes Ct values. 20 Again, as has been discussed above, there is marked variation in the Ct values over time, with apparent reductions in viral RNA being followed by increases, so that one could be misled by trying to track the course of infection by using these values.

Perhaps the longest documented shedding of replication competent SARS-CoV-2 was 238 days in an immunocompromised patient was seen in a patient with mantle cell lymphoma receiving treatment with rituximab, bendamustine and cytarabine. 21

The prognostic utility of the Ct value at or shortly after patient admission was assessed in a 22 retrospective study was performed at two hospitals in New York City 22 . Hospitalized patients testing positive for SARS-CoV-2 by RT-PCR using nasopharyngeal swab specimens collected within a day of J o u r n a l P r e -p r o o f admission were included. RT-PCR was performed using an assay which detects regions of the E gene and the ORF1ab gene, and Ct values from the ORF1ab gene were used to divide the patients into three roughly equally sized groups, with Ct values of <25 (high viral load), 25-30 (medium viral load) and >30

(low viral load). Patients whose samples were positive for the E gene but negative for the ORF1ab gene were included in the low viral load group. A total of 678 patients were studied. There was a strong relationship between the viral load and in-hospital mortality, with mortality rates of 35%, 17.6% and 6.2% for the high, medium and low viral load groups respectively. The proportion of patients who were intubated similarly related to viral load, with 29.1%, 20.8% and 14.9% for the three groups. Finally, multivariate analysis which included multiple risk factors such as age, race and several comorbidities revealed a significantly increased risk of mortality in the high viral load group compared with the low viral load group, with an odds ratio of 6.05 (95% confidence interval 2.92-12.52).

Another approach has been to evaluate the prognostic value of a rising or falling Ct value over time. This was investigated in a retrospective study at a single institution. 23 Patients who presented to the Emergency Department with radiological and clinical evidence of pneumonia who had two or more positive SARS-CoV-2 RT-PCRs with the same assay more than 24 hours apart were included. RT-PCR was performed using an assay that amplifies the N2 and E genes, and the Ct values for the N2 results were analyzed. Clinical status was determined using the sequential organ failure assessment (SOFA) score, which includes scores for six organ systems and predicts clinical outcomes in critically ill patients. Only 

A number of studies have assessed whether lower Ct values can be used to predict who is more likely to transmit SARS-CoV-2. There have been two approaches to this question. Initial studies looked at the relationship between Ct values and viral culture as a proxy for infectivity. These studies required J o u r n a l P r e -p r o o f containment at BL-4 or, more recently, BL-3, and facilities for viral culture, so they could only be performed at a limited number of sites. It is important to bear in mind that the accuracy of viral culture as a surrogate for infectivity of human contacts with an index case is not known, and it is possible that viral culture overestimates or underestimates infectivity of an index case for contacts. The second, more recent approach is to link Ct values determined in routine laboratory testing to transmission events detected in epidemiologic programs meant to reduce transmission. This approach is clearly more powerful than the use of viral culture, but it also has limitations. Specifically, it cannot be definitively determined whether those contacts who become infected after exposure to an index case acquired their infection through that contact or through another contact. This could be evaluated by typing the virus, for example with viral genome sequencing, however such a study has not been done.

One of the earliest studies to evaluate the relationship between Ct values and viral culture results included 183 nasopharyngeal and sputum samples that were positive by RT-PCR for the E gene of SARS-CoV-2. 26 Samples were stored at 4°C for up to 10 hours before being processed for viral culture. Culture A separate study by Bullard et al found similar results, but with some important differences. This study used 90 nasopharyngeal or endotracheal samples that were positive for SARS-CoV-2 using an RT-PCR assay targeting the E-gene. 28 The samples were in viral transport medium and they were stored at 4°C J o u r n a l P r e -p r o o f for 2-3 days and then frozen at -80°C for 2 to 4 weeks. Viral culture with serial dilution of the sample was performed using Vero cells. The authors showed that virus could be detected by culture as long as 8 days after the onset of symptoms and that samples positive by culture had mean Ct values of 17, compared to those that were negative by culture, which had mean Ct values of 27. All samples with virus that was detectable by culture had Ct values below 24. An excellent editorial commentary which accompanied this paper pointed out that the Ct value above which no samples are positive by viral culture varies between studies, and that the effect of storing the samples on the sensitivity of viral culture is unknown. 29 A different group evaluated the relationship between the Ct value and viral culture using 234 samples of several types, 97% of which were from the upper respiratory tract. 30 fold, depending on the Ct value of the sample. The strengths of this study are the large size and the careful analysis by contact type and SARS-CoV-2 variant, which make the results more robust than the previous study and highly generalizable. Similar results were found in a study of the risk of transmission from individuals with different viral loads (not Ct values) in respiratory samples: the secondary attack rate was 12% for index cases with 10 6 or fewer copies of RNA per mL, but 24% for index cases with 10 10 or greater. 36

The decisions of whether and when to report Ct values should be made by the laboratory directors in consultation with local experts in compliance and departmental leadership. If the leadership group decides that Ct values should be reported, several other decisions should be made before proceeding.

The first task is to decide whether all results will be reported or if they will be selectively reported, i.e. upon request. Reporting of all results may cause confusion among caregivers who do not know how to interpret the information, therefore selective reporting would seem to be the better choice. Second, if reporting is to be done selectively, it must be determined who may request the information. One option would be to work with the infectious diseases practitioners at the institution and provide them with the J o u r n a l P r e -p r o o f information needed to understand and utilize these results. If caregivers from other specialties request Ct values, they could be directed to involve infectious diseases specialists so that the information is used appropriately. The third task involves providing the supporting information necessary to help providers correctly interpret a Ct value. Basic information to be provided includes the fact that lower Ct values J o u r n a l P r e -p r o o f

Important Issues to Consider Before Interpreting and Applying Ct Values in Clinical Practice

Mandatory Reporting of COVID-19 Laboratory Test Results: Reporting of Cycle Threshold Values

Committee Perspective: Caution Must Be Used in Interpreting the Cycle Threshold (Ct) Value

Verification and Validation of SARS-CoV-2 Assay

Evaluation of Saline, Phosphate-Buffered Saline, and

Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing

Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR

Validation of SARS-CoV-2 detection across multiple specimen types

Nasal Swab Performance by Collection Timing, Procedure, and Method of Transport for Patients with SARS-CoV-2

Evaluation of Specimen Types and Saliva Stabilization Solutions for SARS-CoV-2 Testing

Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2

Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice

Misinterpretation of viral load in COVID-19 clinical outcomes

with Invasive Mechanical Ventilation for Acute Respiratory Distress Syndrome

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Shedding of Viable SARS-CoV-2 after

Immunosuppressive Therapy for Cancer

Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection

Duration of isolation and precautions in immunocompromised patients with COVID-19

Impact of SARS-CoV-2 Viral Load on Risk of 25

Is Higher Viral Load in SARS-CoV-2 Associated with Death?

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Can the Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Cycle Threshold Value and Time From Symptom Onset to Testing Predict Infectivity? Clin Infect Dis

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance

Ct Values Do not Predict SARS-CoV-2 Transmissibility in College Students

SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission

Transmission of COVID-19 in 282 clusters in

Spain: a cohort study